HK136894A - Process for the lactonization of mevinic acids and analogs thereof - Google Patents

Process for the lactonization of mevinic acids and analogs thereof

Info

Publication number
HK136894A
HK136894A HK136894A HK136894A HK136894A HK 136894 A HK136894 A HK 136894A HK 136894 A HK136894 A HK 136894A HK 136894 A HK136894 A HK 136894A HK 136894 A HK136894 A HK 136894A
Authority
HK
Hong Kong
Prior art keywords
lactonization
analogs
mevinic
acids
mevinic acids
Prior art date
Application number
HK136894A
Other languages
English (en)
Inventor
Laszlo R Treiber
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22827965&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK136894(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of HK136894A publication Critical patent/HK136894A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
HK136894A 1988-07-19 1994-12-01 Process for the lactonization of mevinic acids and analogs thereof HK136894A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/221,475 US4916239A (en) 1988-07-19 1988-07-19 Process for the lactonization of mevinic acids and analogs thereof

Publications (1)

Publication Number Publication Date
HK136894A true HK136894A (en) 1994-12-09

Family

ID=22827965

Family Applications (1)

Application Number Title Priority Date Filing Date
HK136894A HK136894A (en) 1988-07-19 1994-12-01 Process for the lactonization of mevinic acids and analogs thereof

Country Status (26)

Country Link
US (1) US4916239A (fr)
EP (1) EP0351918B1 (fr)
JP (3) JPH0273078A (fr)
KR (1) KR970011286B1 (fr)
CN (1) CN1022831C (fr)
AT (1) ATE111459T1 (fr)
AU (1) AU609319B2 (fr)
CA (1) CA1287639C (fr)
CS (1) CS274640B2 (fr)
CY (1) CY1813A (fr)
DE (1) DE68918191C5 (fr)
DK (1) DK173115B1 (fr)
ES (1) ES2058475T3 (fr)
FI (1) FI92695C (fr)
HK (1) HK136894A (fr)
HR (1) HRP930685B2 (fr)
HU (2) HU202511B (fr)
IE (1) IE64304B1 (fr)
IL (1) IL90925A (fr)
LV (1) LV11033B (fr)
NO (1) NO172800C (fr)
NZ (1) NZ229879A (fr)
PT (1) PT91191B (fr)
SI (1) SI8911362A (fr)
YU (1) YU47492B (fr)
ZA (1) ZA895458B (fr)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof
GB9007738D0 (en) * 1990-04-05 1990-06-06 British Bio Technology Compounds
US5223415A (en) * 1990-10-15 1993-06-29 Merck & Co., Inc. Biosynthetic production of 7-[1',2',6',7',8',8a'(R)-hexahydro-2'(S),6'(R)-dimethyl-8'(S)-hydroxy-1'(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid)
US5250435A (en) * 1991-06-04 1993-10-05 Merck & Co., Inc. Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydroxy-1(S)-naphthyl]-3(R),5(R)-dihydroxyheptanoic acid (triol acid),I)
AU660132B2 (en) * 1992-12-21 1995-06-08 Bayer Aktiengesellschaft Substituted 4-phenyl-pyridones and 4-phenyl-2-alkoxypyridine
DK0680320T3 (da) * 1993-01-19 1999-10-25 Warner Lambert Co Stabilt oralt CI-981-præparat og fremgangsmåde til fremstilling deraf
IN186879B (fr) * 1997-10-28 2001-12-01 Ranbaxy Lab Ltd
IN186880B (fr) * 1997-10-28 2001-12-01 Ranbaxy Lab Ltd
ZA9810764B (en) * 1998-04-22 1999-08-13 Ranbaxy Lab Ltd An improved process of lactonization in the preparation of statins.
CA2240983A1 (fr) 1998-06-18 1999-12-18 Yong Tao Processus de fabrication de simvastatine et de produits intermediaires
AU1683000A (en) * 1998-12-10 2000-06-26 Kaneka Corporation Process for producing simvastatin
SK282679B6 (sk) * 1999-04-16 2002-11-06 Biotika, A. S. Spôsob izolácie lovastatínu z vyfermentovanej pôdy
HUP0103611A2 (en) * 1999-06-29 2009-10-28 Kaneka Corp Process for selective lactonization
WO2001030773A2 (fr) 1999-10-27 2001-05-03 Merck & Co., Inc. Procede de lactonisation
HUP0301214A2 (hu) 2000-03-03 2003-08-28 Plus Chemicals S.A. Tisztítási eljárás csökkentett dimer szennyező tartalmú lovastatin és simvastatin előállítására
NL1017548C2 (nl) * 2001-03-09 2002-09-10 Synthon Bv Een lactonisatie proces.
US6797831B2 (en) * 2001-05-18 2004-09-28 Aurobindo Pharma Limited Process for lactonization to produce simvastatin
KR100407758B1 (ko) * 2001-08-27 2003-12-01 씨제이 주식회사 스타틴의 제조에 있어서 락톤화 방법
KR100502834B1 (ko) * 2002-03-25 2005-07-20 보령제약 주식회사 개선된 락톤화 반응에 의한 심바스타틴의 제조방법 및이의 정제방법
US20050113577A1 (en) * 2002-04-16 2005-05-26 Karki Shyam B. Solid forms of slats with tyrosine kinase activity
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE407670T1 (de) 2002-12-20 2008-09-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer
KR20050098313A (ko) 2003-02-11 2005-10-11 플러스 케미칼스 비.브이. 제어된 범위의 심바스타틴 이량체 함량을 갖는심바스타틴의 제조 방법
AU2004266740B2 (en) 2003-08-21 2010-08-26 Merck Frosst Canada Ltd Cathepsin cysteine protease inhibitors
KR20060109926A (ko) 2003-11-19 2006-10-23 메타베이시스 테라퓨틱스, 인크. 새로운 인-함유 갑상선 호르몬 모방약들
BRPI0418644A (pt) * 2004-03-30 2007-05-29 Lupin Ltd processo para a preparação de um composto
DE602004023004D1 (de) * 2004-09-08 2009-10-15 Jubilant Organosys Ltd Verbessertes verfahren zur lactonisierung bei der herstellung von statinen
CA2581596A1 (fr) * 2004-09-29 2006-04-13 Schering Corporation Combinaisons d'azetidinones substituees et d'antagonistes cb<sb>1</sb>
WO2006059346A2 (fr) * 2004-12-01 2006-06-08 Morepen Laboratories Limited Procede de lactonisation ameliore permettant de produire des statines hautement purifiees
RU2394820C2 (ru) 2004-12-09 2010-07-20 Мерк Шарп Энд Домэ Корп. Модуляторы рецептора эстрогена
DK1855674T3 (da) 2005-03-02 2014-10-20 Merck Sharp & Dohme Sammensætning til hæmning af cathepsin k
US8362075B2 (en) 2005-05-17 2013-01-29 Merck Sharp & Dohme Corp. Cyclohexyl sulphones for treatment of cancer
EP1741427A1 (fr) 2005-07-06 2007-01-10 KRKA, D.D., Novo Mesto Composition pharmaceutique comprenant la simvastatin et l'ezetimibe
WO2007020079A2 (fr) * 2005-08-17 2007-02-22 Synthon B.V. Comprimes de simvastatine a desintegration orale
TW200804345A (en) * 2005-08-30 2008-01-16 Novartis Ag Substituted benzimidazoles and methods of preparation
US20070117996A1 (en) * 2005-11-21 2007-05-24 Srinivasulu Gudipati Process for preparing simvastatin
BRPI0620255A2 (pt) * 2005-12-21 2011-11-08 Schering Corp uso de agentes redutores de colesterol e/ou antagonista/agonista inverso do receptor de h3
WO2007075555A2 (fr) * 2005-12-21 2007-07-05 Schering Corporation Combinaison d'un antagoniste/agoniste inverse de h3 et d'un moderateur de l'appetit
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
PL2010528T3 (pl) 2006-04-19 2018-03-30 Novartis Ag 6-0-podstawione związki benzoksazolowe i benzotiazolowe i sposoby hamowania sygnalizacji csf-1r
EP2059241A1 (fr) * 2006-09-05 2009-05-20 Schering Corporation Compositions pharmaceutiques pour un traitement des lipides et dans le traitement de l'athérosclérose et de la stéatose hépatique
EP2083831B1 (fr) 2006-09-22 2013-12-25 Merck Sharp & Dohme Corp. Procédé de traitement utilisant des inhibiteurs de synthèse d'acide gras
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
SI2805945T1 (sl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Amid substituirani indazoli, kot inhibitorji poli(ADP-riboza)polimeraze(PARP)
EP2132177B1 (fr) 2007-03-01 2013-07-17 Novartis AG Inhibiteurs de pim kinase et procédés de leur utilisation
KR20100017866A (ko) 2007-05-21 2010-02-16 노파르티스 아게 Ｃｓｆ－１ｒ 억제제, 조성물 및 사용 방법
CA2690191C (fr) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. Derives de 4-carboxybenzylamino utilises en tant qu'inhibiteurs de l'histone desacetylase
US20090048335A1 (en) * 2007-08-17 2009-02-19 Venkata Naga Mandava Process for preparing simvastatin
WO2009082437A2 (fr) 2007-12-21 2009-07-02 Ligand Pharmaceuticals Incorporated Modulateurs sélectifs du récepteur androgène (sarm) et leurs utilisations
CA2716671A1 (fr) * 2008-02-27 2009-09-03 Thommen Medical Ag Implant et procede de fabrication
EP2204170A1 (fr) 2008-12-01 2010-07-07 LEK Pharmaceuticals D.D. Composition pharmaceutique comprenant ézétimide et simvastatine
EP2216016A1 (fr) 2009-02-06 2010-08-11 LEK Pharmaceuticals d.d. Procédé pour la préparation d'une composition pharmaceutique comprenant de l'ézétimibe
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
EP2413932A4 (fr) 2009-04-01 2012-09-19 Merck Sharp & Dohme Inhibiteurs de l'activité akt
CA2777043C (fr) 2009-10-14 2015-12-15 Schering Corporation Piperidines substituees qui accroissent l'activite de p53, et utilisations de ces composes
CN104098537A (zh) * 2009-11-20 2014-10-15 北大医药股份有限公司 制备他汀类化合物的内酯化方法
CN101704808A (zh) 2009-11-20 2010-05-12 西南合成制药股份有限公司 制备他汀类化合物的内酯化方法
EP2368543A1 (fr) 2010-03-25 2011-09-28 KRKA, tovarna zdravil, d.d., Novo mesto Procédé de préparation de composition pharmaceutique granulée comprenant de la simvastatine et/ou ézétimibe
US8999957B2 (en) 2010-06-24 2015-04-07 Merck Sharp & Dohme Corp. Heterocyclic compounds as ERK inhibitors
US8518907B2 (en) 2010-08-02 2013-08-27 Merck Sharp & Dohme Corp. RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
EP2606134B1 (fr) 2010-08-17 2019-04-10 Sirna Therapeutics, Inc. Inhibition médiée par des arn interférents de l'expression génique du virus de l'hépatite b (vhb) à l'aide de petits acides nucléiques interférents (pani)
US8883801B2 (en) 2010-08-23 2014-11-11 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors
WO2012030685A2 (fr) 2010-09-01 2012-03-08 Schering Corporation Dérivés d'indazole utilisables en tant qu'inhibiteurs de la voie erk
WO2012036997A1 (fr) 2010-09-16 2012-03-22 Schering Corporation Dérivés condensés de pyrazole utilisés comme nouveaux inhibiteurs erk
EP3766975A1 (fr) 2010-10-29 2021-01-20 Sirna Therapeutics, Inc. Inhibition au moyen d'interférence arn d'une expression de gène utilisant des acides nucléiques à petit interférent (sina)
US9351965B2 (en) 2010-12-21 2016-05-31 Merck Sharp & Dohme Corp. Indazole derivatives useful as ERK inhibitors
US8791162B2 (en) 2011-02-14 2014-07-29 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
WO2012143879A1 (fr) 2011-04-21 2012-10-26 Piramal Healthcare Limited Forme cristalline d'un sel d'un dérivé de morpholinosulfonylindole et son procédé de préparation
US9393224B2 (en) 2011-08-26 2016-07-19 Osaka University Prophylactic and/or therapeutic agent for cardiovascular complications of diabetes
EP2770987B1 (fr) 2011-10-27 2018-04-04 Merck Sharp & Dohme Corp. Nouveaux composés qui sont des inhibiteurs d'erk
EP2597092A1 (fr) 2011-11-24 2013-05-29 Sterling Biotech Limited Procédé de purification de la lovastatine
WO2013165816A2 (fr) 2012-05-02 2013-11-07 Merck Sharp & Dohme Corp. Compositions de petit acide nucléique interférent (sina)
AU2013323508B2 (en) 2012-09-28 2017-11-02 Merck Sharp & Dohme Corp. Novel compounds that are ERK inhibitors
ES2651347T3 (es) 2012-11-28 2018-01-25 Merck Sharp & Dohme Corp. Composiciones y métodos para el tratamiento del cáncer
CA2895504A1 (fr) 2012-12-20 2014-06-26 Merck Sharp & Dohme Corp. Imidazopyridines substituees en tant qu'inhibiteurs de hdm2
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015051479A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Inhibiteurs de cystéine-protéases de type cathepsines
CA2923272A1 (fr) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Inhibiteurs de proteases a cysteine de type cathepsines
EP3094323A4 (fr) 2014-01-17 2017-10-11 Ligand Pharmaceuticals Incorporated Méthodes et compositions pour moduler les taux d'hormone
WO2015120580A1 (fr) 2014-02-11 2015-08-20 Merck Sharp & Dohme Corp. Inhibiteurs de protéases à cystéine de type cathépsines
JO3589B1 (ar) 2014-08-06 2020-07-05 Novartis Ag مثبطات كيناز البروتين c وطرق استخداماتها
EP3525785A4 (fr) 2016-10-12 2020-03-25 Merck Sharp & Dohme Corp. Inhibiteurs de kdm5
WO2019094311A1 (fr) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2020033282A1 (fr) 2018-08-07 2020-02-13 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
EP3833667B1 (fr) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Inhibiteurs de prmt5
WO2021126731A1 (fr) 2019-12-17 2021-06-24 Merck Sharp & Dohme Corp. Inhibiteurs de prmt5
WO2024180169A1 (fr) 2023-03-02 2024-09-06 Carcimun Biotech Gmbh Moyens et procédés de diagnostic du cancer et/ou d'une maladie inflammatoire aiguë

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA81703B (en) * 1980-02-04 1982-09-29 Merck & Co Inc New antihypercholesterolemic compounds,intermediates and processes
JPS5948418A (ja) * 1982-09-10 1984-03-19 Sankyo Co Ltd 高血清過酸化脂質血症治療剤
US4582915A (en) * 1983-10-11 1986-04-15 Merck & Co., Inc. Process for C-methylation of 2-methylbutyrates
US4611068A (en) * 1984-11-19 1986-09-09 Merck Frosst Canada, Inc. Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
US4611067A (en) * 1985-01-31 1986-09-09 Merck & Co., Inc. Process for the preparation of HMG-CoA reductase inhibitors and intermediate compounds employed therein
US4772626A (en) * 1986-01-31 1988-09-20 Merck & Co., Inc. Antihypercholesterolemic compounds
PT85109A (en) * 1986-06-23 1987-07-01 Merck & Co Inc Process for the preparation of hydroxy-tetrahydropyranone derivatives or corresponding ring opened dihydroxy acids which are hmg-coa reductase inhibitors
US4857546A (en) * 1988-01-07 1989-08-15 Merck & Co., Inc. Novel HMG-CoA reductase inhibitors
US4916239A (en) * 1988-07-19 1990-04-10 Merck & Co., Inc. Process for the lactonization of mevinic acids and analogs thereof

Also Published As

Publication number Publication date
NO892938D0 (no) 1989-07-17
CS435489A2 (en) 1990-12-13
LV11033B (en) 1996-06-20
FI92695B (fi) 1994-09-15
ATE111459T1 (de) 1994-09-15
ES2058475T3 (es) 1994-11-01
JP2718422B2 (ja) 1998-02-25
KR910002828A (ko) 1991-02-26
DK173115B1 (da) 2000-01-31
DE68918191C5 (de) 2005-06-09
FI893363A0 (fi) 1989-07-11
CA1287639C (fr) 1991-08-13
JPH09188672A (ja) 1997-07-22
FI92695C (fi) 1994-12-27
EP0351918B1 (fr) 1994-09-14
HUT50804A (en) 1990-03-28
JPH0273078A (ja) 1990-03-13
IL90925A (en) 1993-04-04
DK354189A (da) 1990-01-22
NO892938L (no) 1990-01-22
IE892324L (en) 1990-01-19
JPH0575752B2 (fr) 1993-10-21
CN1039420A (zh) 1990-02-07
DK354189D0 (da) 1989-07-18
AU609319B2 (en) 1991-04-26
IE64304B1 (en) 1995-07-26
CY1813A (en) 1995-10-20
HRP930685B1 (en) 1999-06-30
DE68918191D1 (de) 1994-10-20
US4916239A (en) 1990-04-10
IE892324A1 (en) 1991-06-19
CS274640B2 (en) 1991-09-15
YU136289A (en) 1991-02-28
AU3824089A (en) 1990-01-25
EP0351918A1 (fr) 1990-01-24
ZA895458B (en) 1990-03-28
CN1022831C (zh) 1993-11-24
HRP930685B2 (hr) 2006-11-30
JPH07196642A (ja) 1995-08-01
HU210533A9 (en) 1995-04-28
NZ229879A (en) 1991-12-23
IL90925A0 (en) 1990-02-09
PT91191A (pt) 1990-02-08
SI8911362A (en) 1997-02-28
DE68918191T2 (de) 1995-03-02
PT91191B (pt) 1995-03-01
KR970011286B1 (ko) 1997-07-09
HU202511B (en) 1991-03-28
NO172800B (no) 1993-06-01
HRP930685A2 (en) 1998-06-30
YU47492B (sh) 1995-10-03
FI893363A (fi) 1990-01-20
NO172800C (no) 1993-09-08
LV11033A (lv) 1996-02-20

Similar Documents

Publication Publication Date Title
CY1813A (en) Process for the lactonization of mevinic acids and analogs thereof
HUT63419A (en) Process for producing mercaptoacetamide derivatives of pyrrolo-, pyrido- and oxazinobenzazepine having encephalinase- and angiotensin-converting enzyme-inhibiting activity
PT83077B (en) Process for preparing compactin and mevinolin analogs useful as hmg-coa reductase inhibitors
GR3024255T3 (en) Benzo-fused lactams
GB8811929D0 (en) Phosphorus-containing hmg-coa reductase inhibitors new intermediates &amp; method
JPS6426535A (en) Novel hmg-coa reductase inhibitor
EP0326151A3 (fr) Formulations perfectionnées à libération contrôlée
ES8800244A1 (es) Un procedimiento para preparar naftiridinas antibacterianas
EP0430336A3 (en) Process for the preparation of 4-o-phosphates of dopamine and dopamine derivatives
EP0624574A3 (fr) Analogue de prostaglandine.
GB8811931D0 (en) Phosphorus-containing hmg-coa reductase inhibitors new intermediates &amp; method
EP0307472A4 (fr) Produit immunogene obtenu par expression a partir d&#39;une levure recombinante et procede de purification d&#39;un tel produit.
NO924690L (no) Fremgangsmaate for fremstilling av mono-n-substituerte tetraazakrocykluser
EP0283123A3 (fr) Produits intermédiaires et procédé de préparation d&#39;inhibiteurs de réductase HMG-COA
EP0320052A3 (en) Intermediates and processes for 6-carboxy hmg-coa reductase inhibitors
EP0349060A3 (fr) Procédé de formation de dérivés 6-déméthyl-6-exométhylène de lovastatine et analogues
GR3007199T3 (fr)
IL104135A0 (en) Process for the manufacture of halomaleic and halofumaric esters

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20070717